Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Neurologists

March 24, 2008
Why will Glatiramer work for ALS
By a GLG Expert Contributor
Analysis of: Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis (pharmalive.com)
The phase II trial of Glatiramer acetate for ALS fail to show efficacy. This is not unexpected.
March 19, 2008
More medications for migraine are always in need
By a GLG Expert Contributor
Analysis of: Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache (www.pipelinereview.com)
Current medical treatment is far less from being satisfactory
March 6, 2008
FDA approval of Luvox CR is good news for psychiatrists!
By a GLG Expert Contributor
Analysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder (pharmalive.com)
Luvox was one of the first SSRI's approved for pediatric prescription (for OCD rather than for depression). When patent expired, the maker discontinued manufacture. It has been available in limited supply as generic. Availability of brand-name extended-release product (Luvox CR) will be a significant...
March 6, 2008
Good news for patients with AD or MCI
By a GLG Expert Contributor
Analysis of: Allon's Phase II clinical trial shows statistically significant efficacy on human cognition and memory (www.pipelinereview.com)
WE need more options to fight against AD
February 27, 2008
It is dangerous move
By a GLG Expert Contributor
Analysis of: Google to store patients' health records (news.yahoo.com)
It is not safe place to store personal health information in public search engine.
February 26, 2008
Possibly more ways of fighting against glucocorticoid related osteoporesis
By a GLG Expert Contributor
Analysis of: FORSTEO(R) Receives Positive Opinion from the European Committee for Medicinal Products for Human Use for the Treatment of Glucocorticoid-Induced Osteoporosis (www.pipelinereview.com)
Glucocorticoid-induced osteoporosis has been major problems for the people who use long-term steroid.
February 21, 2008
it is time to fight against big pharm
By a GLG Expert Contributor
Analysis of: Crackdown on Big Pharma (money.cnn.com)
Big pharms have a lot of money to make things to the way they want. Fortunately, someone is trying to make it change
February 21, 2008
More than just AVASTIN
By a GLG Expert Contributor
Analysis of: Genentech has billions at stake in FDA battle (sanfrancisco.bizjournals.com)
Genentech will have more battles to fight in the future aside from Avastin.  This medication appears extremely promising for the treatment of breast cancer, however, physicians are still mixed in their opinions about its place in the treatment of breast cancer.
February 18, 2008
Use of Imported Intermediates or Final Materials for US Drugs Certain to Continue
By a GLG Expert Contributor
Analysis of: China Plant Played Role (online.wsj.com)
The trend to utilize raw materials manufacturers outside the US is driven by dramatic cost savings and is certainly still rising.  Chemistry controls should be specifically targeted to identify impurity profiles in the receipt and release testing of imported material.  FDA could become more...
February 15, 2008
Gamunex in CIDP
By a GLG Expert Contributor
Analysis of: Positive Results from Phase III Trial of Gamunex in Patients with CIDP (pharmalive.com)
IVIg (intraveonus immunoglobulin) reduces disability and reduces risk of relapse in patients with CIDP (chronic inflammatory demyelinating polyradiculoneuropathy).

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next31 to 40 of 109

Analytics


Generated at 2009-01-07T19:00:58.307